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Synaptic vesicle glycoprotein 2A (SV2A) is specifically expressed in the membranes of
synaptic vesicles and modulates action potential-dependent neurotransmitter release.
To explore the role of SV2A in the pathogenesis of epileptic disorders, we recently
generated a novel rat model (Sv2aL174Q rat) carrying a missense mutation of the Sv2a
gene and showed that the Sv2aL174Q rats were hypersensitive to kindling development
(Tokudome et al., 2016). Here, we further conducted behavioral and neurochemical
studies to clarify the pathophysiological mechanisms underlying the seizure vulnerability
in Sv2aL174Q rats. Sv2aL174Q rats were highly susceptible to pentylenetetrazole (PTZ)-
induced seizures, yielding a significantly higher seizure scores and seizure incidence
than the control animals. Brain mapping analysis of Fos expression, a biological marker
of neural excitation, revealed that the seizure threshold level of PTZ region-specifically
elevated Fos expression in the amygdala in Sv2aL174Q rats. In vivo microdialysis study
showed that the Sv2aL174Q mutation preferentially reduced high K+ (depolarization)-
evoked GABA release, but not glutamate release, in the amygdala. In addition, specific
control of GABA release by SV2A was supported by its predominant expression
in GABAergic neurons, which were co-stained with antibodies against SV2A and
glutamate decarboxylase 1. The present results suggest that dysfunction of SV2A by
the missense mutation elevates seizure susceptibility in rats by preferentially disrupting
synaptic GABA release in the amygdala, illustrating the crucial role of amygdalar
SV2A-GABAergic system in epileptogenesis.
Keywords: synaptic vesicle glycoprotein 2A (SV2A), seizure susceptibility, GABA release, glutamate release,
amygdala, pentylentetrazole
INTRODUCTION
Synaptic vesicle glycoprotein 2A (SV2A) is highly expressed in the brain including the
cerebral cortex, limbic regions, and cerebellum, where it modulates action potential-dependent
neurotransmitter release (Crowder et al., 1999; Janz et al., 1999; Xu and Bajjalieh, 2001; Custer
et al., 2006; Chang and Südhof, 2009). Although the functional mechanisms of SV2A remain to
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be clarified, it is suggested that SV2A primes synaptic vesicles
to fully respond to Ca2+ probably by interacting with the
Ca2+ sensor protein synaptotagmin (Xu and Bajjalieh, 2001;
Chang and Südhof, 2009; Nowack et al., 2010). In addition,
previous studies suggest that SV2A plays an important role
in the pathogenesis and treatment of epileptic disorders. This
is because (1) SV2A-knockout mice exhibited severe seizures
(Crowder et al., 1999; Janz et al., 1999), (2) SV2A serves as a
specific binding site for certain antiepileptics (e.g., levetiracetam
and its analogs; Lynch et al., 2004; Pollard, 2008; Kaminski et al.,
2009; Correa-Basurto et al., 2015; Klitgaard et al., 2016) and (3)
the expressional levels of SV2A are reported to be altered in
various epileptic conditions both in animals (e.g., chemically-
and electrically induced kindling) and humans (e.g., intractable
temporal lobe epilepsy and focal cortical dysplasia; Matveeva
et al., 2007; Feng et al., 2009; Ohno et al., 2009a, 2012b; Toering
et al., 2009; van Vliet et al., 2009; Crèvecoeur et al., 2014;
Serajee and Huq, 2015). Furthermore, a recent clinical study
reported that a missense mutation (R383Q) in exon 5 of the SV2A
gene resulted in intractable epilepsy, involuntary movements,
microcephaly and developmental retardation (Serajee and Huq,
2015).
In order to explore the role of SV2A in modulating
development of epileptic disorders (epileptogenesis), we recently
generated a novel rat model (Sv2aL174Q rat) carrying a missense
mutation (L174Q) in the Sv2a gene (Tokudome et al., 2016),
using gene-driven ENU mutagenesis/MuT-POWER techniques
(Mashimo et al., 2008). Sv2aL174Q rats were susceptible to PTZ
seizures and to kindling development associated with repeated
PTZ treatments or focal electrical stimulation of the amygdala.
In addition, the Sv2aL174Q mutation significantly reduced
depolarization-induced GABA release in the hippocampus. These
findings suggest that SV2A plays a crucial role in the kindling
epileptogenesis possibly by interacting GABAergic neurons.
However, the detailed mechanisms underlying the regulation of
seizure susceptibility by SV2A remain to be clarified.
In the present study, therefore, we further conducted
behavioral and neurochemical studies to clarify the mechanisms
(e.g., responsible brain regions and influences on synaptic
amino acid release) underlying the seizure vulnerability in
Sv2aL174Q rats. The present results show that the Sv2aL174Q
mutation elevates excitability of the corticolimbic neural circuit,
especially in the amygdala, by preferentially disrupting synaptic
Abbreviations: AcC, core region of nucleus accumbens; AcS, shell region of
nucleus accumbens; aCSF, artificial cerebrospinal fluid; AIC, agranular insular
cortex; AH, anterior hypothalamus; AM, anteromedial thalamic nucleus; AUC,
area under the curve; AuC, auditory cortex; BLA, anterior basolateral amygdaloid
nucleus; BMA, anterior basomedial amygdaloid nucleus; CA, Cornu Ammonis
area of hippocampus; CgC, cingulated cortex; CM, centromedial thalamic nucleus;
DG, dentate gyrus of the hippocampus; dlST, dorsolateral striatum; DMH,
dorsomedial hypothalamic nucleus; dmST, dorsomedial striatum; ENU, N-ethyl-
N-nitrosourea; FITC, fluorescein isothiocyanate; Gad1, glutamate decarboxylase
1; GP, globus pallidus; LHb, lateral habenular nucleus; LS, lateral septum;
MC, motor cortex; mPFC, the medial prefrontal cortex; Pir, piriform cortex;
PH, posterior hypothalamus; PMCo, posteromedial cortical amygdaloid nucleus;
PRh-Ent, perirhinal-entorhinal cortex; PT, paratenial thalamic nucleus; PTZ,
pentylenetetrazole; SC, sensory cortex; SV2A, Synaptic vesicle glycoprotein 2A;
Syt1, synaptotagmin1; TRITC, tetramethyrhodamine-5-(and 6)- isothiocyanate;
VM, ventromedial thalamic nucleus.
GABA release, illustrating the crucial role of amygdalar SV2A-
GABAergic system in epileptogenesis.
MATERIALS AND METHODS
Animals
Male Sv2aL174Q rats (Tokudome et al., 2016) were obtained from
the National BioResource Project-Rat (F344-Sv2am1Kyo NBRP-
Rat No:0668). The Sv2aL174Q rat, carrying a single nucleotide
mutation T521A, was first identified in a gene-driven ENU
mutagenesis project in Kyoto University (Mashimo et al., 2008).
Thereafter, Sv2aL174Q rats were backcrossed more than five
generations on the F344/NSlc inbred background to eliminate
mutations potentially induced by ENU mutagenesis elsewhere in
the genome. Age-matched male F344 rats (Japan SLC, Shizuoka,
Japan) were used as the control animal. The animals were kept in
air-conditioned rooms under a 12-h light/dark cycle and allowed
ad libitum access to food and water. All animal experiments
were approved by the Animal Research Committees of Osaka
University of Pharmaceutical Sciences and were conducted
according to the Institutional Committees’ regulations on animal
experimentation.
Evaluation of Seizure Susceptibility
To evaluate the seizure sensitivity, Sv2aL174Q or F344 rats were
treated with an intraperitoneal dose of PTZ (30, 35, and 40 mg/kg
for Sv2aL174Q rats; 35, 40, 45, and 50 mg/kg for F344 rats).
PTZ-induced seizures were evaluated over 20 min after the
drug treatment using a 6-point ranked scale as follows, 0: none
response, 1: facial automatisms and twitching of the ears and
whiskers, 2: convulsive waves propagating axially along the trunk,
3: myoclonic convulsions with a delay, 4: clonic convulsions,
5: repeated powerful clonic-tonic or lethal convulsions (Racine,
1972; Franke and Kittner, 2001; Kudryashov et al., 2007). The
incidence of seizures was judged as positive when the animal
showed a seizure score of 3 or more.
Analysis of Fos Protein Expression
To explore causal brain regions for PTZ seizures in Sv2aL174Q
rats, expression of Fos protein, a biological marker of neural
excitation, by the seizure threshold level of PTZ was analyzed.
For this purpose, Sv2aL174Q and F344 rats were cumulatively
injected with an increasing dose of PTZ (first dose: 10 mg/kg,
second dose: 20 mg/kg, third dose: 30 mg/kg) with 30-min
intervals. The incidence of seizures was monitored for 10 min
immediately after each PTZ injection using a seizure scale
described previously. Since the PTZ-induced seizures were
observed only at 30 mg/kg, brain samples were obtained 2 h after
the PTZ (30 mg/kg) injection under pentobarbital (80 mg/kg, i.p.)
anesthesia.
After fixation with 4% formaldehyde solution, coronal
sections (30 µm thickness) were cut from each brain
using a Microslicer (DSK-3000, Dosaka, Kyoto Japan). The
immunostaining of Fos protein was performed using a previously
published method (Ohno et al., 2011, 2012a). Briefly, formalin-
fixed sections were immunohistochemically stained with a goat
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c-Fos antiserum (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) by the ABC method. Fos-immunoreactivity was visualized
by the diaminobenzidine–nickel staining method and quantified
by counting the number of Fos-positive neurons. Brain regions
analyzed includes (1) cerebral cortices: mPFC, CgC, MC, SC,
AIC, Pir, AuC, PRh-Ent; (2) basal ganglia and limbic regions:
AcC, AcS, dlST, dmST, GP, LS, CA, DG, PMCo, BMA, BLA;
(3) diencephalon: LHb, PT, AM, CM, VM, AH, PH, DMH (see
Paxinos and Watson, 2007).
In Vivo Microdialysis Study
Sv2aL174Q or F344 rats were anesthetized with pentobarbital
(40 mg/kg, i.p.) and fixed in a stereotaxic instrument (Narishige,
SR-6, Tokyo, Japan). A guide cannula (1 mm diameter) was
inserted into a position 2 mm above the amygdala (P: 2.8 mm,
L: 4.8 mm, H: −6.1 mm; Paxinos and Watson, 2007) and fixed
to the skull using dental cement. After a recovery period of about
1 week, animals with a chronically implanted guide cannula were
subjected to microdialysis experiments. Briefly, a dialysis probe
(Eicom, A-I-10-02, Kyoto, Japan) was inserted into the amygdala
through a guide cannula and aCSF containing (in mM): NaCl
140, KCl 2.4, MgCl2 1.0, CaCl2 1.2, NaHCO3 5.0, was perfused
at a flow rate of 1 µL/min using a microperfusion pump (Eicom,
ESP-32, Kyoto, Japan). The dialysate samples were collected
into a microtube every 10 min (10 µL/sample). To evaluate
the depolarization-evoked synaptic release, high concentration
(100 mM) K+-containing aCSF was perfused for 60 min through
the dialysis probe.
FIGURE 1 | Seizure susceptibility of Sv2aL174Q rats. (A) Structure of SV2A showing the mutation site L174Q. SV2A possesses a 12-transmembrane structure
which contains a putative binding site for synaptotagmin in the N terminal region and glycosylation sites in a long intravesicular loop between transmembrane regions
7 and 8. (B) Susceptibility of Sv2aL174Q rats to PTZ-induced seizures. Each point represents the mean ± SEM of 8–11 animals. ∗P < 0.05, ∗∗P < 0.01 significantly
different from F344 rats.
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The dialysate samples were analyzed for GABA and glutamate
levels using a HPLC-ECD system. GABA and glutamate
were derivatized with o-phthalaldehyde before the HPLC
injection and separated on a cation exchange column (Eicom,
3.0ϕ × 150 mm; Eicompak SC-5ODS, Kyoto, Japan). The
mobile phase consisted of 0.1 M phosphate buffer, 5 mg/L
EDTA 2Na, pH6.0, with 27% methanol pumped at a flow
rate of 500 µL/min. All data were analyzed by using eDAQ
Power Chrom (eDAQ Pty Ltd, Denistone East, NSW, Australia).
Extracellular GABA and glutamate levels were expressed as
a percentage of the basal control level, which was the mean
of the three points before the high K+ application, in each
animal. The AUC of the high K+-evoked GABA or glutamate
release was also estimated by the trapezoidal approximation
method.
Immunofluorescence Double Staining
Sv2aL174Q or F344 rats were decapitated under pentobarbital
(80 mg/kg, i.p.) anesthesia and brains were removed from the
skull. After fixation with 4% paraformaldehyde solution for
24 h, the brain was dehydrated and embedded in paraffin.
Formalin-fixed and paraffin-embedded amygdaloid tissues were
cut into 4 µm thick sections and the sections were subjected to
immunofluorescence double staining with anti-SV2A and anti-
Gad1 (Ohno et al., 2012b). Sections were incubated with a goat
anti-rat SV2A (dilution 1:500, Santa Cruz Biotechnology, Dallas,
TX, USA) and mouse anti-human Gad1 (dilution 1:1000, Santa
Cruz Biotechnology, Dallas, TX, USA) for 42 h at 4◦C, and
then with an FITC (green fluorescence)-conjugated rabbit anti-
goat IgG secondary antibody (dilution 1:500, Sigma–Aldrich,
St. Louis, MO, USA) and TRITC (red fluorescence)-conjugated
FIGURE 2 | Topographical Fos expression analysis following PTZ-induced seizures. Schematic illustrations of the brain sections selected for quantitative
analysis of Fos protein expression. Filled boxes in each section indicate the sample areas analyzed. Red boxes represent the regions where Fos expression was
significantly elevated by PTZ treatments.
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rabbit anti-mouse IgG secondary antibody (dilution 1:500,
Sigma–Aldrich, St. Louis, MO, USA) to probe SV2A and Gad1,
respectively. Immunofluorescence images were obtained with a
confocal laser scanning microscope (Carl Zeiss Japan, LSM 700
ZEN, Tokyo, Japan). To quantify SV2A and Gad1 expression,
digital images of the amygdala were stored and the integrated
optical density was measured by computer analysis with ImageJ
software (ver. 1.42, NIH).
FIGURE 3 | Regional changes in Fos expression levels by the seizure threshold level of PTZ. Graphs show Fos expression in the cerebral cortical regions
(A), basal ganglia and limbic regions (B), and diencephalon (C). Typical photos of Fos expression in the amygdala are also shown in the right bottom. Each column
represents the mean ± SEM of five Sv2aL174Q (PTZ seizure-positive) and seven F344 (PTZ seizure-negative) rats. ∗P < 0.05, ∗∗P < 0.01 significantly different from
F344 rats. Scale bar: 100 µm.
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Statistical Analysis
Statistical significance of differences between two groups was
performed by Mann–Whitney’s U-test (behavioral scores) or
Student’s t-test (Fos and SV2A expression). Comparisons of
seizure incidence rate were done by X2 test. Differences in
GABA and glutamate release (in vivo microdialysis) were
analyzed by two-way ANOVA followed by Tukey’s post hoc
test. A P-value of less than 0.05 was considered statistically
significant.
RESULTS
Seizure Susceptibility of Sv2aL174Q Rats
Sv2aL174Q rats have a missense mutation T521A in the Sv2a gene,
which results in the substitution of Leu 174 to Gln (Figure 1A).
The mutation site is located in the first transmembrane region
of SV2A that was reportedly essential for the normal function
and structure of SV2A (Chang and Südhof, 2009). In order to
confirm seizure susceptibility of Sv2aL174Q rats, we evaluated
the responses of Sv2aL174Q and F344 rats to PTZ injections
(30–50 mg/kg, i.p.). While gross behaviors of Sv2aL174Q rats
were normal, these animals showed high susceptibility to PTZ
seizures, yielding significantly higher seizure scores at 35 mg/kg
[U(17)= 20.5, P < 0.05] and 40 mg/kg [U(17)= 12.0, P < 0.01],
and a higher seizure incidence at 40 mg/kg (X2 = 6.34, P < 0.05)
than F344 rats (Figure 1B).
Fos Expression Analysis
To explore the brain sites most sensitive to the seizure threshold
level of PTZ, Sv2aL174Q and F344 rats were cumulatively injected
with an increasing dose of PTZ (10, 20, or 30 mg/kg, i.p.) with
FIGURE 4 | Synaptic GABA and glutamate release in the amygdala. (A) GABA release. (B) Glutamate release. Each point represents the mean ± SEM of 10 or
5 animals. Depolarization stimulation was given by applying high concentration (100 mM) K+-containing aCSF (High K+) for 60 min through the dialysis probe. AUC
(the area under the curve) comparisons of GABA and glutamate release are shown in the right. ∗P < 0.05, ∗∗P < 0.01 significantly different from F344 rats. Each
point represents the mean ± SEM of 10 or 5 animals.
Frontiers in Pharmacology | www.frontiersin.org 6 July 2016 | Volume 7 | Article 210
fphar-07-00210 July 12, 2016 Time: 13:18 # 7
Tokudome et al. SV2A Modulates Seizure Susceptibility
30-min intervals. Under these conditions, the first two does did
not evoke any seizure either in Sv2aL174Q or F344 rats. However,
subsequent 30 mg/kg PTZ induced clonic or tonic-clonic seizures
in five out of seven Sv2aL174Q rats while none of seven F344 rats
tested exhibited seizures.
We next compared the expression of Fos protein, a biological
marker of neural excitation, in various regions of the brain
between the Sv2aL174Q (PTZ seizure-positive, N = 5) and F344
(PTZ-negative, N = 7) rats (Figure 2). Sv2aL174Q rats showed
considerably higher Fos expression than F344 rats in most of the
cerebral cortex, reflecting the generalized seizure property of PTZ
seizures (Figure 3A). PTZ-induced Fos expression in Sv2aL174Q
rats were statistically significant in the SC and Pir. On the
other hand, the seizure threshold level of PTZ region-specifically
elevated Fos expression in the amygdala among 21 subcortical
regions examined including basal ganglia, limbic regions, and
diencephalon (Figures 3B,C).
GABA and Glutamate Release in the
Amygdala
Since Sv2aL174Q rats exhibited a region-specific excitation of the
amygdala by PTZ, we conducted in vivo microdialysis studies
to evaluate synaptic release of GABA and glutamate in the
amygdala. As shown in Figure 4A, high K+ (depolarization)
stimuli evoked GABA release both in Sv2aL174Q and F344
rats. However, the depolarization-evoked GABA release was
largely diminished by the Sv2aL174Q mutation [F(1,218) = 56.72,
P < 0.001] (Figure 4A). A comparison of AUC also revealed a
significant reduction in depolarization-evoked GABA release in
Sv2aL174Q rats. On the other hand, in contrast to GABA release,
high K+-evoked glutamate release was not significantly affected
by the Sv2aL174Q mutation (Figure 4B).
SV2A and Gad1 Double Staining in the
Amygdala
We further conducted immunofluorescence double staining of
SV2A with Gad1 (also known as GAD67), a marker protein of
GABAergic neurons, in the amygdala. As shown in Figure 5A,
SV2A (green) was mostly co-stained with Gad1 (red) both in
Sv2aL174Q and F344 rats, illustrating a specific expression of SV2A
in the amygdalar GABAergic neurons. In addition, there were no
significant differences in expressional levels of SV2A and Gad1
between Sv2aL174Q and F344 rats (Figure 5B).
DISCUSSION
The present study confirmed that Sv2aL174Q rats carrying a
missense mutation, L174Q, in the Sv2a gene were highly
sensitive to PTZ-induced seizures, supporting the notion that
SV2A plays the crucial role in controlling seizure susceptibility.
Although a complete deletion of SV2A is known to cause
premature death with severe seizure incidence (Crowder
et al., 1999; Janz et al., 1999), the behavioral phenotype
of Sv2aL174Q rats mimicked those reported in heterozygous
SV2A-deficient mice (Kaminski et al., 2009), implying that
the Sv2aL174Q mutation causes a partial loss of the SV2A
function.
Fos protein is the immediate early gene product and is widely
used as a cellular marker of neural excitation. Specifically, brain
mapping analysis of Fos expression is useful to identify brain
FIGURE 5 | SV2A and Gad1 double staining in the amygdala. (A) Photos showing representative double staining of Gad1 (left: red), SV2A (center: green) in the
amygdala of Sv2aL174Q and F344 rats. Merged photos (right) revealed a predominant co-expression of SV2A with Gad1 (GABAergic neurons) in the amygdala.
(B) Expression levels of SV2A and Gad1 in Sv2aL174Q and F344 rats. ROD, relative optical density. Each column represents the mean ± SEM of four animals. Scale
bar: 50 µm.
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regions related to disease conditions (e.g., epilepsy, emotional
disorders and cognitive impairments) or responses to various
pathophysiological and pharmacological stimuli (e.g., pain, body
temperature, stress, and drug treatments; Morgan and Curran,
1989; Herrera and Robertson, 1996; Ohno et al., 2009b, 2011,
2012a, 2015; Mukai et al., 2013; Fumoto et al., 2014; Iha
et al., 2016). In the present study, we treated animals with
the seizure threshold dose (30 mg/kg, i.p.) of PTZ which
first evoked seizures only in Sv2aL174Q rats. Under these
conditions, the PTZ treatment region-specifically elevated Fos
expression in the cerebral cortex (e.g., SM and Pir), amygdala.
Since PTZ evoked generalized clonic or tonic-clonic seizures
associated with a wide-spread excitation of the cerebral cortex
(Figure 3A), we could not specifically identify the causative
regions in the cortical regions. Nonetheless, the present results
clearly illustrates that the amygdala is most sensitive to and
potential seizure initiation site for PTZ seizures in Sv2aL174Q
rats. In addition, in vivo microdialysis demonstrated that
the Sv2aL174Q mutation preferentially impaired depolarization-
evoked synaptic release of GABA in the amygdala without
affecting glutamate release. These findings provide important
information for our understanding of the SV2A function in
modulating seizure susceptibility. Although the hippocampus
was less sensitive to PTZ seizures than the amygdala, our
results do not deny the potential role of hippocampus in seizure
vulnerability of Sv2aL174Q rats since it is known that PTZ evokes
seizures by activating limbic regions including the hippocampus
(Humpel et al., 1993; Löscher and Ebert, 1996; Szyndler et al.,
2009) and that, indeed, a sufficient dose (70 mg/kg, i.p.) of
PTZ increases Fos expression in the hippocampus (Bastlund
et al., 2005). In addition, we previously demonstrated that
the Sv2aL174Q mutation also disrupted depolarization-evoked
synaptic release of GABA in the hippocampus. Furthermore, the
piriform cortex also seems to be partly involved in the seizure
vulnerability in Sv2aL174Q rats since the threshold level of PTZ
significantly elevated Fos expression in the posterior part of this
structure.
Preferential modulation of synaptic GABA release by
SV2A was further supported by the SV2A expression pattern
in amygdala GABAergic neurons. In that, most of SV2A-
immunoreactivity was expressed in the amygdala neurons and
dendrites, which were co-stained with antibodies against SV2A
and Gad1. These findings are consistent with our previous
findings that SV2A was predominantly expressed in GABAergic
neurons, but only rarely in glutamatergic neurons in the mouse
hippocampus (Ohno et al., 2012b). Therefore, SV2A seems to
specifically regulate synaptic GABA release both in the amygdala
and hippocampus. Since the amygdala and hippocampus are
potential causative sites for various epileptic disorders (Löscher
and Ebert, 1996; Morimoto et al., 2004; Avoli and de Curtis,
2011), the SV2A-GABAergic system in these structures is
likely to be involved in pathogenesis of SV2A-related epileptic
disorders.
The detailed mechanisms underlying SV2A dysfunction by
the Sv2aL174Q mutation are currently unknown. Interestingly, a
previous study showed that the neighboring missense mutations
(D179A and E182A) of the two charged polar amino acids to
the non-polar alanine abolished the normal function of SV2A,
possibly by disrupting the protein folding and/or trafficking
into synaptic membranes (Chang and Südhof, 2009). Thus,
the changes in polarization of the first transmembrane region
by the substitution of hydrophobic non-polar Leu 174 to
polar Gln may impair the integrity of SV2A function. In
addition, we previously showed that the Sv2aL174Q mutation
specifically reduced the expression level Syt1, the Ca2+
sensor protein modulating synaptic release, among exocytosis
regulatory proteins examined (Tokudome et al., 2016). Since
SV2A is suggested to prime synaptic vesicles by interacting
with the Syt1 (Xu and Bajjalieh, 2001; Chang and Südhof,
2009; Nowack et al., 2010), the disruption of synaptic GABA
release by the Sv2aL174Q mutation may result from reduced
expression of Syt1. Further studies are required to delineate
molecular mechanisms of SV2A dysfunction by the Sv2aL174Q
mutation.
The present study supports the clinical view that dysfunction
of SV2A is involved in the pathogenesis of epilepsy, including
intractable temporal lobe epilepsy and focal cortical dysplasia
epilepsy (Feng et al., 2009; Toering et al., 2009; van Vliet et al.,
2009; Crèvecoeur et al., 2014). Indeed, a recent study showed
that a missense mutation R383Q in the SV2A gene caused
intractable epilepsy and involuntary movements, which were
accompanied by developmental retardation (Serajee and Huq,
2015). Thus, the Sv2aL174Q rat may be useful for exploring the
epileptogenic mechanisms of SV2A-related epileptic disorders.
Furthermore, since SV2A is known as a specific binding site
for certain antiepileptics (e.g., levetiracetam, brivaracetam, and
seletracetam; Lynch et al., 2004; Pollard, 2008; Kaminski et al.,
2009; Correa-Basurto et al., 2015; Klitgaard et al., 2016), the
Sv2aL174Q rat may also be useful as a novel animal model
for analyzing the action mechanisms of the levetiracetam-
analogs.
CONCLUSION
We confirmed high susceptibility of Sv2aL174Q rats to PTZ
seizures. Treatment of Sv2aL174Q rats with PTZ at threshold
level specifically elevated Fos expression in the amygdala,
suggesting that the amygdala is the potential site responsible
for seizure vulnerability in Sv2aL174Q rats. In addition, the
Sv2aL174Q mutation preferentially reduced depolarization-evoked
GABA, but not glutamate, release in the amygdala. The
preferential disruption of GABA release due to the Sv2aL174Q
mutation was supported by the specific expression of SV2A
in GABAergic neurons. The present study suggests that
dysfunction of SV2A by the missense mutation elevates seizure
susceptibility by disrupting amygdalar synaptic GABA release,
illustrating the crucial role of the SV2A-GABAergic system in
epileptogenesis.
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